Predicted protein targets (top 16)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | PDPK1 | O15530 | 1/20 | 0.44 |
| ▸ | CYP2A6 | P11509 | 1/20 | 0.39 |
| ▸ | METAP1 | P53582 | 1/20 | 0.38 |
| ▸ | RAB9A | P51151 | 1/20 | 0.36 |
| ▸ | LOXL2 | Q9Y4K0 | 1/20 | 0.35 |
| ▸ | HSP90AA1 | P07900 | 1/20 | 0.34 |
| ▸ | ADORA2A | P29274 | 3/20 | 0.34 |
| ▸ | ADORA1 | P30542 | 2/20 | 0.34 |
| ▸ | ALDH1A1 | P00352 | 1/20 | 0.33 |
| ▸ | TSHR | P16473 | 1/20 | 0.33 |
| ▸ | NOS1 | P29475 | 1/20 | 0.33 |
| ▸ | HSD17B10 | Q99714 | 1/20 | 0.33 |
| ▸ | ADRB2 | P07550 | 1/20 | 0.33 |
| ▸ | SMPD3 | Q9NY59 | 1/20 | 0.32 |
| ▸ | FBP1 | P09467 | 1/20 | 0.31 |
| ▸ | PDK1 | Q15118 | 1/20 | 0.31 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL751581 | 0.75 | HDAC8 (0.33) | METAP1HSP90AA1 | |
| SCHEMBL5067188 | 0.71 | PDPK1 (0.42) | PDPK1CYP2A6METAP1RAB9ALOXL2 | |
| SCHEMBL578376 | 0.71 | PDPK1 (0.52) | PDPK1CYP2A6METAP1RAB9ALOXL2 | |
| SCHEMBL1989627 | 0.71 | CYP19A1 (0.41) | CYP2A6RAB9AALDH1A1HSD17B10 | |
| SCHEMBL5065334 | 0.71 | PDPK1 (0.43) | PDPK1CYP2A6METAP1RAB9ALOXL2 | |
| SCHEMBL28051835 | 0.71 | PDPK1 (0.39) | PDPK1CYP2A6METAP1RAB9ALOXL2 | |
| SCHEMBL102331 | 0.69 | PDPK1 (0.59) | PDPK1CYP2A6METAP1RAB9ALOXL2 | |
| SCHEMBL1671362 | 0.69 | CYP2A6 (0.30) | CYP2A6 | |
| SCHEMBL556950 | 0.69 | PDPK1 (0.54) | PDPK1CYP2A6METAP1RAB9ALOXL2 | |
| SCHEMBL28051848 | 0.68 | PDPK1 (0.36) | PDPK1CYP2A6RAB9ALOXL2HSP90AA1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 17 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| CN-110240792-A | A kind of scratch-resistant high-performance optical diffusion PC material and preparation method thereof | 南通开普乐工程塑料有限公司 | 2019-09-17 | — | — | CN | claimed |
| CN-110669052-B | Substituted 2-azabicyclic compounds and their use as orexin receptor modulators | 詹森药业有限公司 | 2022-10-11 | — | — | CN | disclosed |
| CN-110669052-A | Substituted 2-azabicyclic compounds and their use as orexin receptor modulators | 詹森药业有限公司 | 2020-01-10 | — | — | CN | disclosed |
| CN-105308048-B | Substituted 2-azabicyclic compounds and their use as orexin receptor modulators | 詹森药业有限公司 | 2019-10-08 | — | — | CN | disclosed |
| CN-110240792-A | A kind of scratch-resistant high-performance optical diffusion PC material and preparation method thereof | 南通开普乐工程塑料有限公司 | 2019-09-17 | — | — | CN | disclosed |
| CN-108864093-A | Substituted 2- Azabicyclic compound and their purposes as orexin receptor regulator | 詹森药业有限公司 | 2018-11-23 | — | — | CN | disclosed |
| CN-105308048-A | Substituted 2-azabicyclic compounds and their use as orexin receptor modulators | JANSSEN PHARMACEUTICA NV | 2016-02-03 | — | — | CN | disclosed |
| EP-2854814-A2 | HETEROARYL-KETONE FUSED AZADECALIN GLUCOCORTICOID RECEPTOR MODULATORS | Corcept Therapeutics, Inc. (US) | 2015-04-08 | — | — | EP | disclosed |
| WO-2013177559-A2 | HETEROARYL-KETONE FUSED AZADECALIN GLUCOCORTICOID RECEPTOR MODULATORS | CORCEPT THERAPEUTICS, INC. (US) | 2013-11-28 | — | — | WO | disclosed |
| EP-2178873-B1 | 6-PHENYL-1H-IMIDAZO[4,5-C]PYRIDINE-4-CARBONITRILE DERIVATIVES AS CATHEPSIN INHIBITORS | ORGANON NV (NL) | 2010-12-22 | — | — | EP | disclosed |
| EP-2178873-A1 | 6-PHENYL-1H-IMIDAZO[4,5-C]PYRIDINE-4-CARBONITRILE DERIVATIVES AS CATHEPSIN INHIBITORS | N.V. Organon (NL) | 2010-04-28 | — | — | EP | disclosed |
| EP-1979351-B1 | 6-PHENYL-1H-IMIDAZO[4, 5-C]PYRIDINE-4-CARBONITRILE DERIVATIVES AS CATHEPSIN K AND S INHIBITORS | ORGANON NV (NL) | 2010-04-07 | — | — | EP | disclosed |
| US-7687515-B2 | 6-phenyl-1H-imidazo[4,5-c]pyridine-4-carbonitrile derivatives | N.V. ORGANON (NL) | 2010-03-30 | — | — | US | disclosed |
| WO-2009010491-A1 | 6-PHENYL-1H-IMIDAZO[4,5-C]PYRIDINE-4-CARBONITRILE DERIVATIVES AS CATHEPSIN INHIBITORS | N.V. ORGANON (NL) | 2009-01-22 | — | — | WO | disclosed |
| EP-1979351-A1 | 6-PHENYL-1H-IMIDAZO[4, 5-C]PYRIDINE-4-CARBONITRILE DERIVATIVES AS CATHEPSIN K AND S INHIBITORS | N.V. Organon (NL) | 2008-10-15 | — | — | EP | disclosed |
| US-20070179138-A1 | 6-Phenyl-1H-imidazo[4,5-c]pyridine-4-carbonitrile derivatives | N.V. ORGANON (NL) | 2007-08-02 | — | — | US | disclosed |
| WO-2007080191-A1 | 6-PHENYL-1H-IMIDAZO[4, 5-C]PYRIDINE-4-CARBONITRILE DERIVATIVES AS CATHEPSIN K AND S INHIBITORS | N.V. ORGANON (NL) | 2007-07-19 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20070179138-A1 | 6-Phenyl-1H-imidazo[4,5-c]pyridine-4-carbonitrile derivatives | CTSK, CTSS, CTSZ | PDPK1 193/4885CYP2A6 475/4885METAP1 1202/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.